The goal of this small business technology transfer application is to validate and commercialize an improved means of polyp detection during colonoscopy: spectroscopic microvascular blood assessment from the endoscopically normal mucosa. Missed lesions on colonoscopy are a major problem (conservatively estimated to be ~25% of adenomas and ~4-5% of carcinomas) with devastating clinical and medico-legal consequences. While various adjuvant approaches are being developed, these lack either sensitivity or practicality for clinical medicine. Our breakthrough technology four dimensional elastic light-scattering fingerprinting (4D-ELF) allows unprecedented accuracy in sub-epithelial microvasculature analysis. Using this approach, we have reported, for the first time, that there is an early increase in blood supply (EIBS) in the histologically normal mucosa in experimental animals at risk for colon neoplasia. Thus, EIBS appeared to be an early marker of the """"""""field carcinogenesis"""""""". This was confirmed in human colonoscopic studies using both tissue biopsies and a fiberoptic 4D-ELF probe (~400 patients). Importantly, the increased microvascular blood content was only detectable in the colonic segment (~1/3 of colon) that harbored the lesion and the magnitude mirrored the proximity to the polyp. Based on this preliminary data we hypothesize that real-time EIBS assessment will improve accuracy of neoplasia detection during colonoscopy. In phase 1 of the STTR, we propose to determine threshold (cut-off) levels of microvascular blood content (total and deoxyhemoglobin) for discrimination of colonic segments that harbor neoplasia factoring various potential EIBS modifying factors (age, gender, etc). The milestone for transition into phase 2 of the project will be the development of a highly accurate prediction rule. Phase 2 will consist of a randomized study to assess the impact of real time EIBS information on adenoma detection rate in 1600 patients. Adenoma detection rate with and without EIBS will be compared. Our conservative estimate is that EIBS guidance will improve polyp miss rate by at least a 50%. We believe that EIBS-guidance will allow the endoscopist to rapidly determine whether a colonic segment harbors neoplasia. If EIBS is negative, then rapid visual inspection is possible. Furthermore, it would aid in the relatively common scenarios such as inability to reach cecum or mucosal obscuration by residual stool. If, on the other hand, readings suggest a polyp that is not readily visualizable, then mapping the EIBS magnitude could provide precise localization. Given the clinical promise of this technologically-mature approach, we envision that this can be readily commercialized by American BioOptics through direct manufacturing/distribution of a probe-based system. Alternatively, EIBS detection could be incorporated directly into the colonoscope via parternship with an endoscope company. Most colorectal cancers, the second leading cause of cancer deaths among Americans, arise from polyps. Colonoscopy can identify and remove these polyps thus actually preventing colon cancer. However, at least a quarter of all polyps are missed on colonoscopy leading to cancer deaths and the need to perform more frequent colonoscopies. In our application, we propose to test a novel biomedical optics technology that could both greatly decrease polyp miss rate and also help speed-up the procedures. This could have major importance for colon cancer prevention efforts in the United States. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Technology Transfer (STTR) Grants - Phase II (R42)
Project #
1R42CA130508-01A1
Application #
7394693
Study Section
Special Emphasis Panel (ZRG1-ONC-L (12))
Program Officer
Henderson, Lori A
Project Start
2007-09-28
Project End
2008-08-31
Budget Start
2007-09-28
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$100,007
Indirect Cost
Name
American Biooptics, LLC
Department
Type
DUNS #
783657781
City
Evanston
State
IL
Country
United States
Zip Code
60201
Kunte, Dhananjay P; DelaCruz, Mart; Wali, Ramesh K et al. (2012) Dysregulation of microRNAs in colonic field carcinogenesis: implications for screening. PLoS One 7:e45591
Tiwari, Ashish K; Crawford, Susan E; Radosevich, Andrew et al. (2011) Neo-angiogenesis and the premalignant micro-circulatory augmentation of early colon carcinogenesis. Cancer Lett 306:205-13
Roy, Hemant K; Koetsier, Jennifer L; Tiwari, Ashish K et al. (2011) Involvement of p21cip1/waf1 in the anti-proliferative effects of polyethylene glycol in colon carcinogenesis. Int J Oncol 38:529-36
Roy, Hemant K; Bianchi, Laura K (2010) Moving toward personalization of colorectal cancer screening: Comment on ""Influence of race and sex on prevalence and recurrence of colon polyps"". Arch Intern Med 170:1132-4
Roy, Hemant K; Gomes, Andrew J; Ruderman, Sarah et al. (2010) Optical measurement of rectal microvasculature as an adjunct to flexible sigmoidosocopy: gender-specific implications. Cancer Prev Res (Phila) 3:844-51
Roy, Hemant K; Turzhitsky, Vladimir; Kim, Young et al. (2009) Association between rectal optical signatures and colonic neoplasia: potential applications for screening. Cancer Res 69:4476-83
Gomes, Andrew J; Roy, Hemant K; Turzhitsky, Vladimir et al. (2009) Rectal mucosal microvascular blood supply increase is associated with colonic neoplasia. Clin Cancer Res 15:3110-7
Wali, Ramesh K; Kunte, Dhananjay P; Koetsier, Jennifer L et al. (2008) Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail. Mol Cancer Ther 7:3103-11
Roy, Hemant K; Gomes, Andrew; Turzhitsky, Vladimir et al. (2008) Spectroscopic microvascular blood detection from the endoscopically normal colonic mucosa: biomarker for neoplasia risk. Gastroenterology 135:1069-78